AU2006285177A1 - EP2 receptor agonists for treating glaucoma - Google Patents

EP2 receptor agonists for treating glaucoma Download PDF

Info

Publication number
AU2006285177A1
AU2006285177A1 AU2006285177A AU2006285177A AU2006285177A1 AU 2006285177 A1 AU2006285177 A1 AU 2006285177A1 AU 2006285177 A AU2006285177 A AU 2006285177A AU 2006285177 A AU2006285177 A AU 2006285177A AU 2006285177 A1 AU2006285177 A1 AU 2006285177A1
Authority
AU
Australia
Prior art keywords
group
formula
represented
carbon atoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006285177A
Other languages
English (en)
Inventor
June Chen
David F. Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2006285177A1 publication Critical patent/AU2006285177A1/en
Priority to AU2013200669A priority Critical patent/AU2013200669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2006285177A 2005-08-29 2006-08-21 EP2 receptor agonists for treating glaucoma Abandoned AU2006285177A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013200669A AU2013200669A1 (en) 2005-08-29 2013-02-08 EP2 receptor agonists for treating glaucoma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71258605P 2005-08-29 2005-08-29
US60/712,586 2005-08-29
US11/472,145 US7696235B2 (en) 2005-08-29 2006-06-21 EP2 receptor agonists for treating glaucoma
US11/472,145 2006-06-21
PCT/US2006/032670 WO2007027468A1 (en) 2005-08-29 2006-08-21 Ep2 receptor agonists for treating glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013200669A Division AU2013200669A1 (en) 2005-08-29 2013-02-08 EP2 receptor agonists for treating glaucoma

Publications (1)

Publication Number Publication Date
AU2006285177A1 true AU2006285177A1 (en) 2007-03-08

Family

ID=37529305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006285177A Abandoned AU2006285177A1 (en) 2005-08-29 2006-08-21 EP2 receptor agonists for treating glaucoma

Country Status (7)

Country Link
US (1) US7696235B2 (enExample)
EP (1) EP1919870A1 (enExample)
JP (1) JP2009506113A (enExample)
AU (1) AU2006285177A1 (enExample)
BR (1) BRPI0615245A2 (enExample)
CA (1) CA2602442A1 (enExample)
WO (1) WO2007027468A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007280130B2 (en) * 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
US20090124695A1 (en) 2007-11-14 2009-05-14 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
CN102498101A (zh) * 2009-09-11 2012-06-13 宇部兴产株式会社 苯胺化合物
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20020115695A1 (en) * 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist

Also Published As

Publication number Publication date
BRPI0615245A2 (pt) 2011-05-10
JP2009506113A (ja) 2009-02-12
WO2007027468A1 (en) 2007-03-08
US7696235B2 (en) 2010-04-13
US20070049625A1 (en) 2007-03-01
CA2602442A1 (en) 2007-03-08
EP1919870A1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
EP0789687B1 (en) Ep2-receptor agonists as agents for lowering intraocular pressure
EP1059925B1 (en) Ep2-receptor agonists as neuroprotective agents for the eye
US6090847A (en) EP2 -receptor agonists as neuroprotective agents for the eye
US9890118B2 (en) Prostamides for the treatment of glaucoma and related diseases
US7696235B2 (en) EP2 receptor agonists for treating glaucoma
US8389566B2 (en) Prostaglandins and analogues as agents for lowering intraocular pressure
US20050282912A1 (en) Abnormal cannabidiols as neuroprotective agents for the eye
AU2005262652A1 (en) Abnormal Cannabidiols for lowering intraocular pressure
US20100298436A1 (en) EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists
AU2013200669A1 (en) EP2 receptor agonists for treating glaucoma
US20070015838A1 (en) Cyclopentane n-lower alkyl heptenamide-5-cis-2-(3alpha-hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
AU2006283208B2 (en) Sulfonamides
AU2006283619B2 (en) Novel sulfonamides
HK1032350B (en) Ep2-receptor agonists as neuroprotective agents for the eye

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted